Black Swift Group LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Black Swift Group LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 65.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,897 shares of the company's stock after buying an additional 752 shares during the period. Black Swift Group LLC's holdings in Eli Lilly and Company were worth $1,567,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Knightsbridge Asset Management LLC increased its position in shares of Eli Lilly and Company by 1.9% during the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares in the last quarter. LS Investment Advisors LLC increased its position in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after acquiring an additional 40 shares during the period. Prism Advisors Inc. acquired a new position in Eli Lilly and Company in the 1st quarter valued at about $207,000. CSM Advisors LLC increased its position in Eli Lilly and Company by 30.6% in the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after acquiring an additional 245 shares during the period. Finally, Bfsg LLC increased its position in Eli Lilly and Company by 1.4% in the 1st quarter. Bfsg LLC now owns 2,959 shares of the company's stock valued at $2,444,000 after acquiring an additional 42 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.8%

LLY traded up $6.30 during trading on Friday, hitting $811.73. The company's stock had a trading volume of 2,976,064 shares, compared to its average volume of 2,810,305. The stock has a market cap of $769.30 billion, a PE ratio of 66.05, a PEG ratio of 1.18 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The firm's 50 day moving average price is $771.95 and its 200-day moving average price is $800.51. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company's quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.58 earnings per share. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. Eli Lilly and Company's payout ratio is 48.82%.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Guggenheim boosted their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research report on Friday, July 11th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.